Introduction
Despite significant advances in oncological therapies, cancer remains a major cause of morbidity and mortality. During 2008, 12.7 million new cancer cases were diagnosed worldwide, with 7.6 million cancer-related deaths during that period. In the USA it is estimated that 1500 people die from cancer every day, whereas in the UK, more than one in three people will develop some form of cancer during their lifetime. 1 2 The incidence rate of cancer continues to increase; therefore, anaesthetists are facing the challenge of managing cancer patients with increasing frequency. 3 In many cancers, surgical resection to de-bulk and remove the primary tumour is the mainstay of treatment; however, metastatic recurrence is common. Recent commentary suggests that a number of perioperative factors can directly affect cancer cells and also impact on cell-mediated immunity, thereby potentially promoting the development of metastasis (Table 1) . 4 -6 Here we review the literature on the hypothesis that anaesthetic and analgesic techniques for primary cancer surgery influence long-term outcomes, elucidating the biology of cancer cells and the perioperative factors that could influence metastasis, including the available clinical data.
The literature in this review was obtained from searches ofprocess is dependent upon a myriad of interactions between the immune system of hosts and the tumour's propensity to metastasize. Tumour cells result from a single cell that has undergone multiple cycles of division and mutation. 7 This mutated cell is 'genetically unstable', making it susceptible to the acquisition of additional mutations. The tumour cell becomes refractory to normal signalling cues that regulate cell division and uncontrolled cellular proliferation ensues. 8 Extensive angiogenesis must occur to fulfil the increasing demands of the evolving tumour. Indeed, tumours cannot survive beyond 2 mm in diameter without angiogenesis. 9 The process of angiogenesis is stimulated by the release of pro-angiogenic factors from the tumour, including vascular endothelial growth factor (VEGF) and prostaglandin E 2 .
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Following the establishment of this new capillary network, an aggregate of cells detaches from the primary tumour and invades surrounding tissues. Penetration of the basement membrane signifies transformation from a benign carcinoma in situ to an invasive malignant tumour. The cancer cells access the systemic circulation by penetrating thin-walled vessels, including lymphatics. The majority of invading cancer cells are destroyed by the immune system, with ,0.1% of cells being viable after 24 h. A specific subset of macrophages, CD11b+, recognize breast cancer metastatic cells and assist with their progression. 11 Surviving cancer cells migrate to the capillary bed of a distant organ where they continue to proliferate within the vessel wall and later, within the parenchyma of the organ.
Cancer and the immune system
Cell-mediated immunity forms the primary defence against the invasion of tumour cells and its major components include natural killer (NK) cells, cytotoxic T cells, mononuclear cells, and dendritic cells. NK cells are large, granular cytotoxic lymphocytes that recognize tumour cells spontaneously, without prior sensitization, and induce lysis. 5 12 There is an association between stress-induced attenuation of NK cell activity and the promotion of breast tumour growth and metastasis in a rat model 13 The immune system is modulated by multiples of cytokines, some of which are associated with promotion of cancer, while others resist it. Manipulation of the immune system to produce an enhanced anti-tumour response could be utilized as an adjuvant oncological therapy. Recombinant NK T cells, for example, have proposed therapeutic potential. 16 A promising survival benefit was observed when rats received 'immunostimulation' therapy perioperatively. 17 The effect of surgery per se on host immune function and metastasis
Surgical excision is frequently an essential component of cancer management and it offers the best opportunity for a good prognosis in patients with solid tumours. 5, 6 However, it is known that surgical excision of the tumour can inadvertently facilitate the metastasic process. 18 Even with successful excision to histologically negative margins, 'minimal residual disease' remains, as a result of inadvertent dispersal of tumour 'emboli' during surgery, or pre-existing 'micrometastases'. The ongoing presence of neoplastic cells in the circulation 24 h after resection is independently associated with increased risk of cancer recurrence. 19 The fate of this minimal residual disease is critically dependent upon the perioperative immune competence of the host. However, major surgery is associated with a neuroendocrine and cytokine 'stress response', 20 which induces transient suppression of cell-mediated immunity during this vulnerable period, when it might be determined whether metastasis will be established or eradicated. 21 Several studies using animal models have demonstrated that tumour growth and metastasis are enhanced by surgery. For example, it was demonstrated in a mouse model that laparotomy increased the number of liver metastases from 15 to 34. 22 The proposed mechanisms by which surgery promotes metastasis include the following factors:
( (a) Increased plasma levels of VEGF-in a mouse model, the stress of surgery (laparotomy or mastectomy) or chronic stress significantly increased tumour mass associated with increased postoperative levels of VEGF. 27 28 (b) Decreased plasma levels of endostatin and angiostatin-endostatin is an endogenous anti-angiogenic mediator, formed by the fragmentation of collagen and significantly reduced lung cancer metastasis in a mouse model.
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Effect of anaesthesia per se on host immune function and cancer
Experimental evidence from a rat inoculation model of breast cancer suggests that ketamine, thiopental, and older volatile anaesthetics increase tumour metastasis, in an inverse relationship with NK cell activity. 30 Sevoflurane binds lymphocyte antigens, interfering with their activity. 31 Isoflurane and sevoflurane have been shown to induce apoptosis in human T-lymphocytes in vitro in a dose-dependent manner. 32 While activation of an inositol trisphosphate (IP 3 ) mechanism has been found by which isoflurane induces apotosis in chicken-derived B-lymphocytes in vitro.
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A recent review suggested that volatile anaesthetics upregulate hypoxia-inducible factor (HIF-1a) in neoplastic cells, which increases angiogenesis and is associated with poor patient prognosis. 34 An experimental study using human colon cancer cells found that isoflurane exposure (30 min at 1.2%) was not associated with induction of apoptosis in these cells in vitro. 35 Furthermore, a number of volatile agents altered gene expression in two separate cancer cell lines, breast carcinoma, and neuroblastoma in vitro. 36 On the other hand, another in vitro study demonstrated that pre-treating human neutrophils with sevoflurane and desflurane inhibited the release of MMP-9 by 40% (for both agents). As a result, migration of colon cancer cells was inhibited. 37 
Nitrous oxide
Nitrous oxide has been associated with a number of immune modulating effects in experimental and clinical studies. A follow-up study of a previous randomized, controlled trial initially designed to evaluate surgical site infection, in which patients who underwent colectomy for cancer were randomized to receive either 65% nitrous oxide (N 2 O) and oxygen or 65% nitrogen and oxygen, in combination with isoflurane and remifentanil. Patients who received N 2 O showed no significant difference in cancer recurrence compared with those receiving nitrogen and oxygen (P¼0.72).
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Propofol
Propofol significantly decreased the production of prostaglandin E 2 by human monocytes in vitro. However, it is unclear whether this effect is related to the proposed antineoplastic effect of propofol. 39 In a rat model of breast cancer, propofol was not associated with an increase in LTR, nor did it suppress NK cell cytotoxicity. 30 
Ketamine
Ketamine has exhibited immunomodulatory effects on macrophages, lymphocytes, and mast cells in experimental studies. It inhibited dendritic cell-mediated maturation of T cells in a mouse model; however, the ketamine concentration used was two to three times higher than that used in the clinical setting. 40 In another study, ketamine (10 mg kg 21 ) exerted inhibitory effects on NK cell cytotoxicity in vitro, using a rat model. 41 The effect of low-dose ketamine (0.15 mg kg 21 ) i.v., 5 min before induction of GA, on immune function in patients undergoing elective abdominal surgery in a randomized controlled trial, was examined. It indicated that ketamine attenuated production of the pro-inflammatory cytokines, IL-6, and TNF-a and suppressed NK cell cytotoxicity after operation. 42 
Local anaesthetics
Local anaesthetics (LAs) have proposed cytotoxic effects on neoplastic cells. An anti-proliferative effect on human tongue cancer cells, by inhibiting epidermal growth factor, was exhibited by lidocaine in vitro. 43 Lidocaine, bupivacaine, and ropivacaine reduced mesenchymal stem cell proliferation in vitro and transcription pathways related to initiation of neoplasia and metastasis were also inhibited. 44 LAs have also been reported to alter the DNA methylation status of certain cancer cell types and have been associated with the reactivation of tumour suppressor genes. 45 LAs have also been associated with cytotoxic effects on Tlymphoma cells in vitro. Apoptosis was observed at lower concentrations, while necrosis was seen at higher concentrations. Eight LAs were studied in total and each exhibited varying cytotoxic effects, which appeared to correlate with their lipophilicity and potency. 46 a 2 -Adrenoceptor agonists a 2 -Adrenoceptors are expressed on human breast cancer cell lines and stimulation of these receptors is associated with increased proliferation. 47 Clonidine has been shown to modulate NK cell activity and to enhance cellular proliferation in vitro and in vivo.
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Effect of opioids on host immune function and cancer
Opioids are frequently prescribed for cancer patients for the management of acute postoperative pain and for chronic pain. In addition to their analgesic effects, opioids have wellestablished immunomodulatory effects. Evidence from experimental studies in cancer is conflicting. 48 This is further complicated by the fact that the type of opioid, route, and duration of administration might all be relevant confounding factors. 49 Inflammatory cytokines have been shown to regulate the expression of the m-opioid receptor (MOR) gene, 50 highlighting an interaction between the opioid and immune systems. 51 Opioids inhibit components of both cell-mediated and humoral immunity. 49 52 However, all opioids do not suppress immune function to the same degree. Morphine has been demonstrated to decrease toll-like receptor (TLR) expression on macrophages by direct stimulation of the MOR in an animal model. 53 Fentanyl (40 mg kg 21 ) 1 h before a laparotomy was shown to depress NK cell function in a rat model. A rapid increase in NK cell activity was seen during the first 24 h, but this was followed by significantly decreased activity, only returning to baseline activity levels after 8 days. 41 It is theorized that activation of specific genes during the perioperative period can contribute to cancer recurrence and metastasis. The NET1 gene has been shown to promote migration in adenocarcinoma cell lines. Breast cancer cells (both ER-positive and ER-negative) were shown to express MOR and morphine not only increased cancer cell migration, it also induced higher levels of the NET1 gene, known to promote adenocarcinoma, which seemed to mediate its increased migration effect. 54 
Effect of opioids on tumour development
It has been proposed that opioids exert their effects on tumour growth by direct stimulation of the MOR; however, there are also suggestions that these effects are mediated through activation of VEGF receptors. However, as yet, clinical evidence is unclear. Extended exposure to high concentrations of opioids can suppress tumour growth whereas a single-dose or low-dose opioid can promote tumour growth. 55 The MOR is over-expressed in several types of non-small cell lung cancer. Silencing the MOR, using a knockout technique, significantly reduced opioid-induced tumour growth (35 -50%) and metastasis (45 - 59 MORs have been demonstrated in the nuclei of human colon cancer cells. Exposure of these cells to morphine, at a concentration of 0.1 mM for 24 h, was associated with a significant increase in secretion of urokinase plasminogen activator, suggesting a potential association between morphine and the invasive properties of the tumour. 60 However, opioids can also paradoxically suppress tumour migration and proliferation in limited circumstances. In an experimental model of breast cancer, morphine inhibited cancer-promoting MMP-2 and MMP-9 production in a dosedependent manner, mediated by the nitric oxide (NO) system. 59 Some studies have shown that morphine lowers MMP-9, increases the MMP inhibitors TIMP-1 and -2 or both in co-cultured breast cancer and macrophages or endothelial cells. Morphine has been associated with inhibition of the adhesion and migration of colon cancer cells in vitro. In addition, an inhibitory effect on MMP production by the tumour cells was also observed. 61 Opioids also tend to induce apoptosis in cancer cells through the NO pathway with activation of nuclear factor (NF)-kB, a potent transcription factor in the regulation of inflammation and apotosis. 62 Morphine, at clinically relevant doses, was shown to induce apoptosis in lung carcinoma and in promyelocytic leukaemia cell lines in vitro.
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Effect of opioids on angiogenesis
Singleton and Moss observed that opioid-stimulated angiogenesis could be reversed by MNTX directly through inhibition of the MOR. MOR inhibition resulted in reciprocal inhibition of VEGF receptors. This group also demonstrated a synergistic effect between MNTX and other chemotherapeutic agents, such as 5-fluorouracil and bevacizumab. 64 This could potentially reduce the required therapeutic dose of these cytotoxic agents and consequently reduce unwanted side-effects. Mechanisms proposed to explain the effect of morphine on angiogenesis include upregulation of COX-2 and increased PGE2 production. 65 Nonetheless, chronic high-dose morphine inhibited angiogenesis in an animal model of lung cancer. VEGF secretion was reduced by 50% under hypoxic conditions and tumour progression reduced significantly, an effect attributed to attenuated angiogenesis. Differences in morphine dose and route of administration, different tumour cell lines and the effect of withdrawal or tolerance have been proposed as an explanation for these discrepancies.
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Effects of endogenous opioids b-Endorphin is an endogenous opioid that affects the physiological stress response. Enhanced endogenous b-endorphin production increases NK cell cytotoxicity and antiinflammatory cytokines and decreased pro-inflammatory cytokines (TNF-a). Perhaps the anti-neoplastic properties of b-endorphin are related to attenuation of the stress response. b-Endorphin has been suggested as a potential therapeutic cancer agent. 67 A specific polymorphism of the MOR gene (A118G) might be associated with improved cancer survival rates at 10 yr. This study included more than 2000 female patients with breast cancer. Patients with invasive cancer who had one or more G alleles had a significantly decreased mortality rate at 10 yr. 68 A number of confounding factors in this study should be considered, including the use of strong opioids, ongoing chemotherapy, and perception of pain. 49 
Effect of pain
The implications of inadequately controlled pain on the stress response should be considered if future strategies seek to limit opioids perioperatively. Opioid analgesia and intrathecal bupivicaine significantly decreased postoperative LTR compared with no analgesia in a live animal model of breast cancer, 69 demonstrating that effective perioperative analgesia can play a role in facilitating resistance to metastatic progression.
Role of cyclo-oxygenase (COX) inhibitors and prostaglandins in immunomodulation and promotion of tumour growth
Prostaglandins (PGs) are derived from arachidonic acid, which is converted to PGs by one of the two types of COX: COX-1 is a
Effect of anaesthetic and analgesic techniques on cancer recurrence or metastasis Continued constitutive enzyme, whereas COX-2 is expressed during inflammation and is induced by cytokines and growth factors. PGs activate the inflammatory response and are believed to promote cancer cell adhesion, migration, and invasion, inducing a response that favours neoplasia. 70 PGs can directly influence immune function by inhibiting the activity of cytotoxic T cells and dendritic cells, down-regulating the anti-neoplastic cytokines, TNF-a and INF-g and up-regulating the immunosuppressive cytokines IL-10, 1L-4 and 1L-6.
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The activity of COX can also convert pro-carcinogens to carcinogens which induce mutagenesis and initiate tumour formation. 72 Over-expression of COX-2 and increased production of PGE 2 have been observed in a range of cancers of epithelial origin, including colorectal, breast, bladder, cervical, and ovarian. Given this trend, it is plausible that inhibition of PG synthesis using COX inhibitors might reduce progression of cancer.
There is epidemiological evidence that the long-term use of COX inhibitors reduces the risk of cancer, in particular, breast, colon, lung, and prostate cancer. 72 A standard daily dose of celecoxib, a selective COX-2 inhibitor, was associated with a 69% risk reduction in a case -control study of patients with colorectal cancer. 72 A recent prospective cohort study with over 2.5 million patient-years of follow-up over 10 years demonstrated that the use of any COX inhibitor was associated with a 20% reduced risk of colorectal cancer. 73 COX-2 is frequently over-expressed in breast cancer and PGE 2 is believed to contribute its metastatic potential. A meta-analysis of the effects of aspirin and ibuprofen on .520 000 patients demonstrated that they were associated with decreased risk of developing breast cancer. 74 However, the prolonged use of specific COX-2 inhibitors can cause cardiovascular morbidity. 75 In the absence of a prospective, randomized trial, it is impossible to state whether perioperative COX inhibition can affect cancer recurrence rates.
Regional anaesthesia
Regional anaesthesia attenuates the neuroendocrine stress response, reducing opioid, and intraoperative volatile anaesthetic agent requirements. 76 This combination of effects might allow enhanced preservation of perioperative immune function and possibly reduce the incidence of cancer recurrence. Addition of spinal to GA reduced lung metastasis following laparotomy compared with GA alone. 77 Another study reported similar results that spinal anaesthesia was associated with preservation of NK cell function in vitro. 22 However, a recent meta-analysis found no association between regional anaesthesia and the preservation of NK T-lymphocyte function after operation when compared with GA.
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Small prospective clinical studies randomized patients undergoing breast cancer surgery to receive either GA with propofol, in addition to continuous paravertebral anaesthesia and analgesia (PVA), or GA with sevoflurane and opioid analgesia. While propofol with continuous PVA attenuated the stress response, no difference in VEGF and PGE 2 concentrations was observed. 10 But serum from patients randomized to propofol -PVA, as a putative 'anti-cancer' anaesthetic, showed greater inhibitory effects on oestrogen receptornegative breast cancer cell function than the serum of patients who had received standard GA.
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A long-term follow-up analysis of the MASTER trial, a multicentre prospective clinical study in which patients undergoing major abdominal surgery were randomized to receive GA with either epidural or opioid analgesia found no difference in cancer-free survival between the groups. The median time to cancer recurrence or death was 2.6 yr in the epidural group, when compared with 2.8 yr in the opioid group. This was the first long-term follow-up of patients prospectively randomly assigned to either opioid or epidural analgesia. A potential confounding factor might have been the amount of volatile anaesthesia required intraoperatively, which was 
Effect of allogeneic blood transfusion
Allogenic blood transfusion is associated with modulation of the immune system and might also be associated with increased risk of cancer recurrence, perioperative infections, and mortality. 80 Transfused leucocytes can be involved in transfusion-related immunomodulation, leading to alterations in circulating lymphocytes, helper T-cell, suppressor T-cell ratios, and B-cell function. Irradiated or leucocytedepleted red cells are frequently administered to cancer patients, but an association between patients who received leucocyte-depleted red cells and significantly decreased disease-free survival and overall survival, compared with patients who did not receive a transfusion has been observed. 81 A recent meta-analysis examined the effect of transfusion on cancer recurrence, disease-free survival, and overall survival in patients undergoing surgery for resection of lung cancer in 5378 patients. No definitive conclusions could be established; however, there appeared to be an association been transfusion and reduction of disease-free survival.
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Effect of psychological stress on cancer recurrence
Up to 30% of women with breast cancer suffer from anxiety and depression, and a history of depression might predict cancer recurrence and overall survival. 83 The psychological stress and anxiety endured perioperatively stimulates the physiological stress response through the HPA axis and the sympathetic nervous system. This leads to secretion of glucocorticoids, endogenous opioids, and catecholamines, which exerts a significant impact on the tumour microenvironment. It is proposed that b-adrenoreceptor antagonists might inhibit some of the deleterious effects of stress. Women who were taking the non-selective b-antagonist propranolol during the year before the diagnosis of breast cancer were less likely to have local tumour invasion at presentation and had a lower incidence of cancer-related mortality compared with women who did not. This effect was not observed in patients taking the selective b 1 -antagonist atenolol, but the small numbers of women in the propranolol cohort and the retrospective data indicate that these results should be interpreted cautiously. 84 
Effect of perioperative hypothermia on cancer recurrence
Inadvertent perioperative hypothermia is experienced by up to 70% of patients under anaesthesia as a result of cool ambient theatre temperature, blunted thermoregulation as a result of anaesthesia and convective air streams in theatre.
Hypothermia induces changes at a cellular level that negatively impact innate and adaptive immunity. Incubation of human monocytes from healthy volunteers at 348C for 4 h was associated with inhibition of antigen presentation as assessed by HLA-DR expression. Cytokine secretion was also decreased. A recent cohort study assessed the effect of hypothermia (,368C) in patients with advanced ovarian cancer undergoing debulking surgery. Hypothermia was associated with a significantly reduced overall survival, at 34 months compared with 45 months. 85 Retrospective clinical evidence of an association between regional anaesthesia and cancer recurrence
There have been a number of retrospective analyses regarding the implications of regional anaesthesia during cancer surgery for a variety of tumours on recurrence, metastases, and survival, which have yielded conflicting evidence. These are summarized, together with follow-up analysis of some previous randomized, controlled trials (FARCTs) designed to evaluate non-cancer outcomes, in Table 2 . 86 -99 A recent large-scale database study found that the use of epidural analgesia with GA during colorectal cancer surgery was associated with improved 5 yr survival (61 vs 56% for patients who had GA only), but not with any difference in cancer recurrence as assessed by referral for chemotherapy or radiotherapy. 99 Perhaps the effect of regional anaesthesia is tumour-specific; however, discrepancies remain. Retrospective studies are inherently susceptible to selection bias and are useful only to highlight associations and generate hypotheses. Only prospective, multicentre, randomized, controlled trials can confirm a causal link, and these are ongoing in a number of tumour types, which are summarized in Table 3 .
Conclusion
Some, but not all, experimental, animal and retrospective clinical evidence indicate an association between anaesthetic technique and cancer recurrence, but only prospective, randomized, clinical trials can prove a causal link. These are ongoing, randomizing patients with primary cancer to receive an 'anti-cancer' anaesthetic technique (consisting of regional anaesthesia with propofol based GA) or standard GA with opioid analgesia, and the results are eagerly awaited; this will take a further 3-7 yr. Meanwhile, there is no evidence to support altering current routine clinical anaesthetic practice in cancer patients undergoing surgery.
